# Intravitreal Aflibercept Injection or Early Vitrectomy for Diabetic Vitreous Hemorrhage

> **NCT04153253** · PHASE4 · COMPLETED · sponsor: **Al Hadi Hospital** · enrollment: 34 (actual)

## Conditions studied

- Diabetic Vitreous Hemorrhage

## Interventions

- **DRUG:** Aflibercept Injection [Eylea]
- **PROCEDURE:** Vitrectomy

## Key facts

- **NCT ID:** NCT04153253
- **Lead sponsor:** Al Hadi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-07
- **Primary completion:** 2019-07-22
- **Final completion:** 2019-09-29
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2020-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04153253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04153253, "Intravitreal Aflibercept Injection or Early Vitrectomy for Diabetic Vitreous Hemorrhage". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04153253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*